Altace Patent Suit Cited By Icahn In Latest Missive Against Mylan/King Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor maintains that Cobalt Pharmaceuticals' patent challenge could mean a generic version of the ACE inhibitor will be launched in mid-2005. Mylan suggests that Icahn's opposition is motivated in part by desire to cash-in on short position in King.
You may also be interested in...
Pharma Mergers Will Be More Defensive Going Forward, Abbott CEO Says
Investor wariness on the economic benefit of acquisitions will slow consolidation in the industry, White tells The Economist Pharmaceutical Roundtable. Sanofi-Aventis expects that any further consolidation will result from weakness.
Pharma Mergers Will Be More Defensive Going Forward, Abbott CEO Says
Investor wariness on the economic benefit of acquisitions will slow consolidation in the industry, White tells The Economist Pharmaceutical Roundtable. Sanofi-Aventis expects that any further consolidation will result from weakness.
King's Review Of Product Returns Could Scuttle Mylan Merger
Both companies say the issues stem from historical practices and will not affect King's business going forward. Mylan says it remains committed to acquiring King but seeks further quantification of any financial restatement relating to King's recognition of product returns.